nach oben

Erschienen in:

01.09.2013 | Preclinical study

Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade

verfasst von: Beatriz Martinez-Delgado, Mercedes Gallardo, Miljana Tanic, Kira Yanowsky, Lucia Inglada-Perez, Alicia Barroso, Maria Rodriguez-Pinilla, Marta Cañamero, Maria A. Blasco, Javier Benitez

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Telomere shortening is a common event involved in malignant transformation. Critically short telomeres may trigger chromosomal aberrations and produce genomic instability leading to cancer development. Therefore, telomere shortening is a frequent molecular alteration in early stages of many epithelial tumors and in breast cancer correlates with stage and prognosis. A better understanding of the involvement of short telomeres in tumors may have a significant impact on patient management and the design of more specific treatments. To understand the role of telomere length (TL) in breast cancer etiology we measured the length of individual telomere signals in single cells by using quantitative telomere in situ hybridization in paraffin-embedded tissue from hereditary and sporadic breast cancers. A total of 104 tumor tissue samples from 75 familial breast tumors (BRCA1, n = 14; BRCA2, n = 13; non-BRCA1/2, n = 48) and 29 sporadic tumors were analyzed. Assessment of telomere signal intensity allowed estimation of the mean TL and related variables, such as percentage of critically short telomeres and percentage of cells with short telomeres. These data were correlated with the immunohistochemical expression of molecular breast cancer markers. Hereditary BRCA1, BRCA2, and non-BRCA1/2 tumors were characterized by shorter TL comparing to sporadic tumors. Considering all tumors, tumor grade was a strong risk factor determining the proportion of short telomeres or short telomere cells. Moreover, some histopathological features appeared to be differentially associated to hereditary or sporadic subgroups. Short telomeres correlated with ER-negative tumors in sporadic cases but not in familial cases, whereas a high level of apoptosis was associated with shorter telomeres in hereditary BRCA1 and BRCA2 tumors. In addition, TL helped to define a subset of non-BRCA1/2 tumors with short telomeres associated with increased expression of antiapoptotic proteins. These findings highlight the potential interest of TL measurements as markers of aggressiveness in breast cancer.

Nur mit Berechtigung zugänglich

Artandi SE, DePinho RA (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9–18PubMedCrossRef

Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622PubMedCrossRef

Prescott J, Wentzensen IM, Savage SA, De VI (2012) Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat Res 730:75–84PubMedCrossRef

Broccoli D, Godley LA, Donehower LA, Varmus HE, de LT (1996) Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 16:3765–3772PubMed

Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG et al (2004) In situ analyses of genome instability in breast cancer. Nat Genet 36:984–988PubMedCrossRef

Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ et al (2002) Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 62:6405–6409PubMed

Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY et al (2004) Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 10:3317–3326PubMedCrossRef

van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL et al (2002) Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161:1541–1547PubMedCrossRef

Vera E, Canela A, Fraga MF, Esteller M, Blasco MA (2008) Epigenetic regulation of telomeres in human cancer. Oncogene 27:6817–6833PubMedCrossRef

10.

Meeker AK, Argani P (2004) Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 9:285–296PubMedCrossRef

11.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

12.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef

13.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef

14.

Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef

15.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRef

16.

Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD et al (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12:27–34PubMedCrossRef

17.

Gown AM (2009) Tweaking and nudging toward improved-IHC quality. Appl Immunohistochem Mol Morphol 17:363–365PubMedCrossRef

18.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

19.

Tang P, Skinner KA, Hicks DG (2009) Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 18:125–132PubMedCrossRef

20.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al (2009) Ki67 index, HER2 status, and prognosis of patients with Luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef

21.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRef

22.

Heaphy CM, Subhawong AP, Gross AL, Konishi Y, Kouprina N, Argani P et al (2011) Shorter telomeres in Luminal B, HER-2 and triple-negative breast cancer subtypes. Mod Pathol 24:194–200PubMedCrossRef

23.

Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121PubMedCrossRef

24.

Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22PubMedCrossRef

25.

Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4:174–191PubMedCrossRef

26.

Martinez-Delgado B, Yanowsky K, Inglada-Perez L, Domingo S, Urioste M, Osorio A et al (2011) Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 7:e1002182PubMedCrossRef

27.

Ballal RD, Saha T, Fan S, Haddad BR, Rosen EM (2009) BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. J Biol Chem 284:36083–36098PubMedCrossRef

28.

McPherson JP, Hande MP, Poonepalli A, Lemmers B, Zablocki E, Migon E et al (2006) A role for Brca1 in chromosome end maintenance. Hum Mol Genet 15:831–838PubMedCrossRef

29.

Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM et al (2010) BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol 17:1461–1469PubMedCrossRef

30.

Osorio A, Barroso A, Martinez B, Cebrian A, San Roman JM, Lobo F et al (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82:1266–1270PubMedCrossRef

31.

Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312PubMedCrossRef

32.

Flores I, Canela A, Vera E, Tejera A, Cotsarelis G, Blasco MA (2008) The longest telomeres: a general signature of adult stem cell compartments. Genes Dev 22:654–667PubMedCrossRef

33.

Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA (2000) Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26:114–117PubMedCrossRef

34.

Munoz P, Blanco R, Flores JM, Blasco MA (2005) XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet 37:1063–1071PubMedCrossRef

35.

Samper E, Goytisolo FA, Slijepcevic P, van Buul PP, Blasco MA (2000) Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang. EMBO Rep 1:244–252PubMedCrossRef

36.

Zijlmans JM, Martens UM, Poon SS, Raap AK, Tanke HJ, Ward RK et al (1997) Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc Natl Acad Sci USA 94:7423–7428PubMedCrossRef

37.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9:3606–3614PubMed

38.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90:5–14PubMedCrossRef

39.

Sabine VS, Faratian D, Kirkegaard-Clausen T, Bartlett JM (2012) Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer. Histopathology 60:369–371PubMedCrossRef

40.

Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A et al (2008) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27:3165–3175PubMedCrossRef

41.

Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S et al (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 11:R47PubMedCrossRef

42.

Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C et al (2010) Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 12:R42PubMedCrossRef

43.

Ellsworth RE, Hooke JA, Love B, Kane JL, Patney HL, Ellsworth DL et al (2008) Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors. Breast Cancer Res Treat 107:259–265PubMedCrossRef

44.

Kronenwett U, Ploner A, Zetterberg A, Bergh J, Hall P, Auer G et al (2006) Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol Biomarkers Prev 15:1630–1635PubMedCrossRef

45.

Odagiri E, Kanada N, Jibiki K, Demura R, Aikawa E, Demura H (1994) Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 73:2978–2984PubMedCrossRef

46.

Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE, Moyzis RK (1999) Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 54:59–64PubMedCrossRef

47.

Poonepalli A, Banerjee B, Ramnarayanan K, Palanisamy N, Putti TC, Hande MP (2008) Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. Genes Chromosomes Cancer 47:1098–1109PubMedCrossRef

48.

Jin Y, Stewenius Y, Lindgren D, Frigyesi A, Calcagnile O, Jonson T et al (2007) Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res 13:1703–1712PubMedCrossRef

49.

Stewenius Y, Jin Y, Ora I, de Kraker J, Bras J, Frigyesi A et al (2007) Defective chromosome segregation and telomere dysfunction in aggressive Wilms’ tumors. Clin Cancer Res 13:6593–6602PubMedCrossRef

50.

Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A et al (2006) Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 99:193–202PubMedCrossRef

51.

Ducray C, Pommier JP, Martins L, Boussin FD, Sabatier L (1999) Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene 18:4211–4223PubMedCrossRef

52.

Cheung AL, Deng W (2008) Telomere dysfunction, genome instability and cancer. Front Biosci 13:2075–2090PubMedCrossRef

53.

Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S et al (1993) Correlations between apoptotic and proliferative indices in malignant non-Hodgkin’s lymphomas. Am J Pathol 142:755–763PubMed

54.

Lipponen PK, Aaltomaa S (1994) Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173:333–339PubMedCrossRef

55.

Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K (1994) Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A:2068–2073PubMedCrossRef

56.

Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127–134PubMed

57.

Nasu S, Yagihashi A, Izawa A, Saito K, Asanuma K, Nakamura M et al (2002) Survivin mRNA expression in patients with breast cancer. Anticancer Res 22:1839–1843PubMed

58.

Izawa A, Kobayashi D, Nasu S, Saito K, Moriai R, Asanuma K et al (2002) Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer. Anticancer Res 22:2965–2969PubMed

59.

Lv YG, Yu F, Yao Q, Chen JH, Wang L (2010) The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis 2:100–110PubMed

60.

Tischkowitz MD, Foulkes WD (2006) The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 5:963–967PubMedCrossRef

61.

Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853PubMedCrossRef

62.

Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascon A et al (2007) Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 20:1298–1306PubMedCrossRef

63.

Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van LI et al (2006) Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res 12:1693–1700PubMedCrossRef

Titel: Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade
verfasst von: Beatriz Martinez-Delgado
Mercedes Gallardo
Miljana Tanic
Kira Yanowsky
Lucia Inglada-Perez
Alicia Barroso
Maria Rodriguez-Pinilla
Marta Cañamero
Maria A. Blasco
Javier Benitez
Publikationsdatum: 01.09.2013
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2696-6

Springer Medizin

Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC

Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women

Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells

Vegetable protein and vegetable fat intakes in pre-adolescent and adolescent girls, and risk for benign breast disease in young women

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie